The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Eli Lilly And Company accounts for 5.72 % of our USA Portfolio. A trade is currently open since 06/30/2020 with a purchase price of $ 161.35. Discover the other 19 stocks of the USA portfolio managed by the MarketScreener portfolio management team.
Strengths
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Analysts covering this company mostly recommend stock overweighting or purchase.
The stock is in a well-established, long-term rising trend above the technical support level at 156.88 USD
Weaknesses
Stock prices approach a strong long-term resistance in weekly data at USD 216.96.
Technically, the stock approaches a strong medium-term resistance at USD 214.26.
The company's "enterprise value to sales" ratio is among the highest in the world.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
